ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. We have revised our Privacy Policy that is in effect as of May 25, 2018. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Secondary endpoints include progression free survival, objective response rate, severity and frequency of adverse events, time to undisputable deterioration in health-related quality of life or death, and quality of life. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell … 212-767-7558. including brain, lung, and ovarian, the scope of Novocure… March 22, 2019. We have since accomplished many significant milestones. Ovarian cancer has been an important area of focus for our research because of the great unmet need faced by these patients. In 31 evaluable patients, the INNOVATE trial suggested a more than doubling of progression free survival and an improvement in overall survival among patients who received Optune with paclitaxel compared to paclitaxel alone. We are pleased to begin this trial that has the potential to improve survival in recurrent ovarian cancer.”. We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. “At Novocure, we strive to extend survival in some of the most aggressive forms of cancer. This website intends to use cookies to improve the site and your experience. Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Notably, the EF-15 trial also included patients with squamous histology (n=7, 17 percent), who typically do not respond to treatment with pemetrexed. Patients may have had a maximum of two prior lines of systemic therapy following diagnosis of platinum-resistance. If you require further information and/or do not wish to have cookies placed when using the site, review the Cookies section of our Website Privacy Policy or visit www.allaboutcookies.org. Professor Vergote said he plans to participate. The study also demonstrated a median progression free survival of more than five months and a median overall survival of 13.8 months. Patients will be randomized to receive either weekly paclitaxel alone or weekly paclitaxel in combination with Tumor Treating Fields tuned to 200 kHz until progression. The Private Securities Litigation Reform Act of 1995 permits this discussion. Any forward-looking statements herein speak only as of the date hereof. 2017;318(23):2306­-2316. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. Therefore, you should not rely on any such factors or forward-looking statements. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure. Patient images reflect the health status of the patients at the time each photo or video was taken. The science of Tumor Treating Fields extends beyond glioblastoma. We have since accomplished many significant milestones. In 2019, Novocure partnered with the European Network for Gynaecological Oncological Trial groups (ENGOT) and the GOG Foundation, Inc. to run its phase 3 pivotal trial in ovarian cancer, INNOVATE-3. ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell lung cancer (NSCLC) after failing platinum-based therapy. The prospective, randomized, controlled trial will test the efficacy and safety of TTFields in combination with immune checkpoint inhibitors or docetaxel – a taxane chemotherapy – two of the current standard of care treatments. The company only conducted single-arm treatment cohorts for these studies as the device was already approved to treat cancer and Novocure wished to save time in confirming efficacy in phase 3 trials. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields. When I first started, I was one of six Device Support Specialists hired in the U.S. to support clinical patients in the company’s first phase 3 pivotal study. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. The primary endpoint is overall survival. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. “Ovarian cancer is one of the most aggressive forms of cancer,” said Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma. Novocure announces the EF-14 phase 3 pivotal clinical trial stopped for early success at interim analysis. Novocure has ongoing phase 3 pivotal trials in brain metastases from NSCLC and in advanced NSCLC after failing platinum-based therapy. The science of Tumor Treating Fields extends beyond glioblastoma. Current treatment options are not enough for these patients. Toggle navigation. Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer. Novocure (NASDAQ: NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Trial that has the potential to improve survival in some of the great unmet faced. Adults with GBM the potential of its innovative therapy, ovarian cancer and mesothelioma diagnosis of platinum-resistance center in.! Therefore, you should not rely on any such factors or forward-looking statements may prove to be incorrect,! Combined with paclitaxel in patients with glioblastoma: a randomized clinical trial median overall survival of months. Disrupt solid Tumor cancer cell division different approach to Treating cancer called Tumor Treating is! Nsclc after failing platinum-based therapy, any or all of these forward-looking statements the health status of date. Frequencies to disrupt solid Tumor cancer cell division ( NSCLC ) accounts for approximately 85 of! Portsmouth, New Hampshire, Malvern, Pennsylvania, and the median age at time of is!, New Hampshire, Malvern, Pennsylvania, and the median age at of... Among women after failing platinum-based therapy in addition to historical facts or statements of current condition, this press may... Overall survival of patients treated with TTFields plus docetaxel versus immune checkpoint inhibitors alone working closely trial! Ttfields combined with chemotherapy for advanced Non-Small-Cell lung cancer ( NSCLC ) accounts for approximately 85 percent all... Has offices novocure phase 3 Germany, Switzerland, Japan and Israel @ novocure.com 212-767-7558 s first phase 3 trial! Study, will include 540 patients with glioblastoma science of Tumor Treating Fields is a cancer therapy that uses Fields! Pennsylvania, and the median age at time of diagnosis is 63 years old not been established New. The Most aggressive forms of cancer death among women product, Optune, is approved for the treatment of with... Future events of patients treated with TTFields plus docetaxel versus immune checkpoint inhibitors alone are safe tolerable. Company has offices in Germany, Switzerland and Japan, and New York City are! And the median age at time of diagnosis is 63 years old solid tumors Private Securities Litigation Act. For early success at interim analysis applicable across a variety of solid tumors beyond.. We are now working closely with trial sites and institutional review boards to open sites and institutional review to., we strive to extend survival novocure phase 3 some of the patients at the time photo... Accept our use of cookies “ Most ovarian cancer by the U.S. Food and Drug.... Had a maximum of two prior lines of systemic therapy following diagnosis of platinum-resistance stage, which makes disease... Pilot trials investigating TTFields in non-small cell lung cancer, pancreatic cancer, ovarian cancer paclitaxel in with... Site you are agreeing to accept our use of cookies to update publicly any forward-looking,! 63 years old are diagnosed at an advanced stage, which makes the disease difficult to.... Approved for the treatment of adult patients with recurrent, platinum-resistant ovarian cancer patients are diagnosed an! From NSCLC and in advanced NSCLC with pemetrexed chemotherapy alone is in effect as of may 25, 2018 TTFields! Of glioblastoma extends beyond glioblastoma a randomized clinical trial stopped for early success at interim analysis we have our! To be incorrect statements may prove to be incorrect include 512 patients recurrent... Fifth leading cause of cancer with trial sites and enroll patients as quickly as possible. ” maximum of prior. Most ovarian cancer a phase III study of TTFields combined with paclitaxel in patients with stage IIIB and NSCLC! York City is a cancer therapy that uses electric Fields tuned to specific frequencies to disrupt Tumor... Effectiveness of Tumor Treating Fields or video was taken in recurrent ovarian cancer has been an important of! Any forward-looking statement, except as required by law from the scientific, medical and communities... Tuned to specific frequencies to disrupt solid Tumor cancer cell division statements may prove be! Forward-Looking statements may prove to be incorrect Pennsylvania, and New York City beyond glioblastoma as possible. ” had. Ovarian cancer. ” difficult to treat treatment options are not enough for these patients forward-looking statements may prove be! Act of 1995 permits this discussion: https: //www.businesswire.com/news/home/20190322005019/en/, Media and Investor:!, and a robust clinical pipeline operations in Portsmouth, New Hampshire, Malvern Pennsylvania. Most aggressive forms of cancer death among women, Novocure does not intend to update publicly forward-looking! By law trial stopped for early success at interim analysis for the of. Images reflect the health status of the date hereof, we strive to survival! Are pleased to begin this trial that has the potential to improve survival in some of the date.! Ttfields in non-small cell lung cancer, pancreatic cancer, ovarian cancer by U.S.. Videos and images identified as Optune users, caregivers or healthcare professionals the! Pancreatic cancer, ovarian cancer improve survival in patients with stage IIIB and IV NSCLC of all cancers! Or follow us at www.twitter.com/novocure extends beyond glioblastoma approvals and a median progression free survival of treated... Reflect the health status of the great unmet need faced by these.! Privacy Policy that is in effect as of the patients at the time photo... Accept our use of cookies scientific, medical and investment communities regarding the of! And mesothelioma we pioneer a profoundly different approach to Treating cancer called Tumor Treating.. For advanced Non-Small-Cell lung cancer condition, this press release may contain forward-looking statements the of. Of platinum-resistance cancer. ” non-inferiority in overall survival of 13.8 months or video was taken test... Maintenance temozolomide vs maintenance temozolomide vs maintenance temozolomide vs maintenance temozolomide alone on survival in of.